Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium

被引：0
|
作者：
Van, Nooten F. [1 ]
Dewilde, S. [1 ]
Van Belle, S. [2 ]
Marbaix, S. [3 ]
机构：
[1] United BioSource Corp, Brussels, Belgium
[2] State Univ Ghent Hosp, B-9000 Ghent, Belgium
[3] Pfizer, Brussels, Belgium
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A329 / A329
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain
    Emiliano Calvo Aller
    Pablo Maroto
    Noémi Kreif
    José Luis González Larriba
    Marta López-Brea
    Daniel Castellano
    Belén Martí
    Silvia Díaz Cerezo
    Clinical and Translational Oncology, 2011, 13 : 869 - 877
  • [22] Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain
    Calvo Aller, Emiliano
    Maroto, Pablo
    Kreif, Noemi
    Gonzalez Larriba, Jose Luis
    Lopez-Brea, Marta
    Castellano, Daniel
    Marti, Belen
    Diaz Cerezo, Silvia
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (12): : 869 - 877
  • [23] COST-EFFECTIVENESS EVALUATION OF SUNITINIB AS FIRST-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN KAZAKHSTAN
    Kostyuk, A.
    Nurgozhin, T.
    Mazhitov, T.
    Almadiyeva, A.
    VALUE IN HEALTH, 2014, 17 (03) : A85 - A85
  • [24] COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
    Robert, J.
    Culine, S.
    Roupret, M.
    Zhong, Y.
    Prabhu, V. S.
    Xu, R.
    Li, H.
    Lafuma, A.
    Bensimon, L.
    Clement, A.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [25] COST-EFFECTIVENESS ANALYSIS OF SUNITINIB VERSUS INTERFERON ALFA FOR THE FIRST-LINE TREATMENT OF ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA IN SINGAPORE
    Pruis, S.
    Pearce, F.
    Aziz, Abdul M., I
    Wu, D. B.
    Ng, K. H.
    VALUE IN HEALTH, 2018, 21 : S15 - S15
  • [26] Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.
    Lauren, Brianna
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Ostvar, Sassan
    Laszkowska, Monika
    Chu, Jacqueline N.
    Manji, Gulam Abbas
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States
    Delea, Thomas E.
    Amdahl, Jordan
    Diaz, Jose
    Nakhaipour, Hamid Reza
    Hackshaw, Michelle D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (01): : 46 - U135
  • [28] Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
    Lauren, Brianna
    Ostvar, Sassan
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Laszkowska, Monika
    Chu, Jacqueline N.
    Hershman, Dawn L.
    Manji, Gulam
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [29] Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer
    Levy-Piedbois, C
    Durand-Zaleski, I
    Juhel, H
    Schmitt, C
    Bellanger, A
    Piedbois, P
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 157 - 161
  • [30] Cost-Effectiveness of Pazopalb Versus Sunitinib for Renal Cancer in the United States
    Benedict, Agnes
    Ramaswamy, Krishnan
    Sandin, Rickard
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2015, 21 (09): : 834 - 836
12345